+44 20 8123 2220
info@marketpublishers.com

Atopic Dermatitis - Pipeline Insight, 2021

https://marketpublishers.com/r/A80C2107FA09EN.html
Date: May 2021
Pages: 120
Price: US$ 2,500.00 (Single User License)
ID: A80C2107FA09EN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Atopic Dermatitis – Pipeline Insight, 2021," report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Atopic Dermatitis Understanding

Atopic Dermatitis: Overview

Atopic dermatitis (AD) also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood, but can occur at any age and can be recurrent or persistent throughout life. In the word 'dermatitis,' 'derm' means 'skin' and 'itis' means 'inflammation.' Thus, dermatitis is a skin inflammation characterized by itchiness, redness and a rash caused by genetics, an overactive immune system, infections, allergies, and irritating substances. Half of the patients with moderate-to-severe eczema also have asthma, hay fever (allergic rhinitis), and food allergies. It is the most common chronic skin disease in children. The primary symptom of AD is dry, itchy skin that often turns into a red rash. During a flare, AD becomes a red, itchy rash. Many different physical and internal factors can trigger an eczema flare-

+44 20 8123 2220
info@marketpublishers.com

up. The exact cause of AD is unknown. The basic understanding of AD is that inflammation results from the presence of too many inflammatory cells in the skin. There is also evidence that people with AD have a compromised skin barrier compared to normal skin. Currently, there is no specific test for AD, and no single symptom or feature can be used to identify the disease. Each patient has a unique combination of symptoms and rash appearance. Diagnosis of AD is based on the history and physical examination of the patient. In uncertain cases, a skin biopsy may be taken for a histopathological diagnosis of dermatitis. Currently, there is no cure for AD; however, it can be effectively managed with current treatment options.

'Atopic Dermatitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atopic Dermatitis pipeline landscape is provided which includes the disease overview and Atopic Dermatitis treatment guidelines. The assessment part of the report embraces, in depth Atopic Dermatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atopic Dermatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Atopic Dermatitis R&D. The therapies under development are focused on novel approaches to treat/improve Atopic Dermatitis.

Atopic Dermatitis Emerging Drugs Chapters

This segment of the Atopic Dermatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Atopic Dermatitis Emerging Drugs

Abrocitinib: Pfizer

+44 20 8123 2220
info@marketpublishers.com

Abrocitinib (PF-04965842) is an oral, small molecule that selectively inhibits Janus kinase (JAK) 1. Inhibition of JAK1 modulates multiple cytokines involved in the pathophysiology of AD, including interleukin (IL)-4, IL-13, IL-31, IL-22, and thymic stromal lymphopoietin (TSLP). The drug received breakthrough therapy designation from the FDA to treat patients with moderate-to-severe AD in February 2018. In October 2020, based on the results of a robust Phase III clinical trial program, the FDA, accepted the filing of the company's NDA for abrocitinib (100 mg and 200 mg) and granted priority review designation; the decision is anticipated April 2021. EMA accepted the MAA for the drug in the same patient population with a decision anticipated in the second half of 2021.

Upadacitinib: AbbVie

Upadacitinib (ABT-494) was discovered and developed by AbbVie. It is a selective and reversible JAK inhibitor that was approved by FDA and EMA in August 2019 and December 2019, respectively, for adult patients with moderately to severely active rheumatoid arthritis. The drug is currently under clinical developmental studies for atopic dermatitis, and several other immune-mediated diseases. %li%In October 2020, AbbVie submitted an application to the FDA and EMA seeking approval for Rinvoq for the treatment of adults (15 mg and 30 mg, once daily) and adolescents (15 mg, once daily) with moderate-to-severe AD. The atopic dermatitis indication applications to the FDA and EMA are supported by data from three pivotal Phase 3 studies.

Tradipitant: Vanda Pharmaceuticals

Tradipitant is a small molecule based neurokinin 1 (NK1) receptor antagonist. Tradipitant is currently in phase III clinical development for gastroparesis, COVID-19 pneumonia, motion sickness and atopic dermatitis. Tradipitant licensed by Vanda from Eli Lilly and Company (Lilly) in April 2012. The patent describing tradipitant as a new chemical entity expires worldwide in April 2023, except in the United States, where it expires in June 2024.

Nemolizumab: Galderma

+44 20 8123 2220
info@marketpublishers.com

Nemolizumab (CD14152) is a subcutaneously administered monoclonal antibody that antagonizes IL-31RA, a cytokine that plays a key role in the pathogenesis of moderate-to-severe AD, thereby blocking IL-31 signaling on its effector cells, including peripheral neurons. The drug was initially developed by Chugai Pharmaceutical and subsequently licensed to Galderma in 2016. Currently, the drug is being studied in Phase III trial as a once-daily oral therapy for moderate-to-severe AD in adults and in several other immune-mediated diseases.

Lebrikizumab: Eli Lilly and Company

Lebrikizumab is a novel, investigational, monoclonal antibody designed to bind IL-13 with very high affinity, specifically preventing the formation of the IL-13R?1/IL-4R? heterodimer complex and subsequent signaling, thereby inhibiting the biological effects of IL-13 in a targeted and efficient fashion. IL-13 is believed to be a central pathogenic mediator that drives multiple aspects of the pathophysiology of atopic dermatitis by promoting type 2 inflammation and mediating its effects on tissue, resulting in skin barrier dysfunction, itch, skin thickening, and infection. The drug is being evaluated in Phase III stage of development for the treatment of patients with Atopic dermatitis.

IDP 124: Ortho Dermatologics

Bausch Health Americas in collaboration with Ortho Dermatologics is developing IDP 124 for the treatment of patients with Atopic dermatitis. The drug is currently in phase 3 of clinical trials.

SHR0302: Reistone Biopharma

SHR0302 is a highly selective small molecule based JAK 1 inhibitor. Reistone licensed in the drug from Jiangsu Hengrui Medicine and owns the global rights for multiple indications of autoimmune diseases. Reistone Biopharma is developing SHR0302 in linical studies with both oral and topical dosage forms for several immune-inflammatory diseases including Ulcerative Colitis, Crohn's disease, etc. The high selectivity of SHR0302 may potentially provide a favorable safety and efficacy profile compared to the pan-JAK inhibitors.

MEDI3506: AstraZeneca

+44 20 8123 2220
info@marketpublishers.com

MEDI 3506 is an IL-33 (interleukin-33) monoclonal antibody being developed by AstraZeneca for the treatment of Atopic Dermatitis and chronic diabetic kidney disease. The drug is currently being studied in phase II stage of development for the treatment of patients with Atopic Dermatitis.

Further product details are provided in the repor

Atopic Dermatitis: Therapeutic Assessment

This segment of the report provides insights about the different Atopic Dermatitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Atopic Dermatitis

There are approx. 100+ key companies which are developing the therapies for Atopic Dermatitis. The companies which have their Atopic Dermatitis drug candidates in the most advanced stage, i.e. Phase III include, Lysogene.

Phases

DelveInsight’s report covers around 100+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

+44 20 8123 2220
info@marketpublishers.com

Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Atopic Dermatitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atopic Dermatitis therapeutic drugs key

+44 20 8123 2220
info@marketpublishers.com

players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atopic Dermatitis drugs.

Atopic Dermatitis Report Insights

- Atopic Dermatitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs

Atopic Dermatitis Report Assessment

- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Atopic Dermatitis drugs?
- How many Atopic Dermatitis drugs are developed by each company?

+44 20 8123 2220
info@marketpublishers.com

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atopic Dermatitis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Atopic Dermatitis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Atopic Dermatitis and their status?

What are the key designations that have been granted to the emerging drugs?

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Atopic Dermatitis - Pipeline Insight, 2021
Product link: https://marketpublishers.com/r/A80C2107FA09EN.html
Price: US$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/A80C2107FA09EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970